Industry Strength Score
54/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
KYVERNA THERAPEUTICS INC (KYTX) Stock Price & Overview
NASDAQ:KYTX • US5019761049
Current stock price
8.87 USD
+0.07 (+0.8%)
At close:
8.77 USD
-0.1 (-1.13%)
After Hours:
The current stock price of KYTX is 8.87 USD. Today KYTX is up by 0.8%. In the past year, price increased by 289.04%.
KYTX Key Statistics
52-Week Range1.92 - 13.67
Current KYTX stock price positioned within its 52-week range.
1-Month Range8.25 - 11.62
Current KYTX stock price positioned within its 1-month range.
- Market Cap
- 536.901M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.65
- Dividend Yield
- N/A
KYTX Stock Performance
Today
+0.8%
1 Week
-2.10%
1 Month
N/A
3 Months
+10.74%
Longer-term
6 Months +27.26%
1 Year +289.04%
2 Years -29.21%
3 Years N/A
5 Years N/A
10 Years N/A
KYTX Stock Chart
KYTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to KYTX. When comparing the yearly performance of all stocks, KYTX is one of the better performing stocks in the market, outperforming 97.7% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
KYTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KYTX. KYTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
KYTX Earnings
Next Earnings DateMay 19, 2026
Last Earnings DateMar 26, 2026
PeriodQ4 / 2025
EPS Reported-$0.80
Revenue Reported
EPS Surprise 8.62%
Revenue Surprise %
KYTX Forecast & Estimates
12 analysts have analysed KYTX and the average price target is 30.19 USD. This implies a price increase of 240.38% is expected in the next year compared to the current price of 8.87.
Analysts
Analysts85
Price Target30.19 (240.36%)
EPS Next Y14.67%
Revenue Next YearN/A
KYTX Index Membership
KYTX is currently included in the following stock indexes tracked on ChartMill.
KYTX Financial Highlights
Over the last trailing twelve months KYTX reported a non-GAAP Earnings per Share(EPS) of -3.65. The EPS decreased by -5.19% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-161.31M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.9% | ||
| ROE | -69.45% | ||
| Debt/Equity | 0.11 |
Chartmill High Growth Momentum
EPS Q2Q%9.09%
Sales Q2Q%N/A
EPS 1Y (TTM)-5.19%
Revenue 1Y (TTM)N/A
KYTX Ownership
Ownership
Inst Owners72.54%
Shares60.53M
Float55.27M
Ins Owners0.02%
Short Float %7.66%
Short Ratio4.86
KYTX Industry Overview
KYTX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 412 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 412
- New Highs
- 4.6%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.9%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.1
KYTX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.53 | 365.426B | ||
| AMGN | AMGEN INC | 13.77 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.63 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 26.24 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.4 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.43 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KYTX
Company Profile
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company is headquartered in Emeryville, California and currently employs 129 full-time employees. The company went IPO on 2024-02-08. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The firm is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Company Info
IPO: 2024-02-08
KYVERNA THERAPEUTICS INC
5980 Horton Street, Suite 550
Emeryville CALIFORNIA US
Employees: 129
Phone: 15106268331
KYVERNA THERAPEUTICS INC / KYTX FAQ
What does KYTX do?
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company is headquartered in Emeryville, California and currently employs 129 full-time employees. The company went IPO on 2024-02-08. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The firm is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
What is the current price of KYTX stock?
The current stock price of KYTX is 8.87 USD. The price increased by 0.8% in the last trading session.
Does KYTX stock pay dividends?
KYTX does not pay a dividend.
What is the ChartMill rating of KYVERNA THERAPEUTICS INC stock?
KYTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of KYTX stock?
KYVERNA THERAPEUTICS INC (KYTX) has a market capitalization of 536.90M USD. This makes KYTX a Small Cap stock.
Can you provide the upcoming earnings date for KYVERNA THERAPEUTICS INC?
KYVERNA THERAPEUTICS INC (KYTX) will report earnings on 2026-05-19.